Drug Development Pipeline
GS-5745 is an antibody that may help reduce inflammation in the lungs, leading to improved lung function in people with CF.
A phase 2 study to test the effectiveness of GS-5745 in adults with CF was stopped in 2017. The decision to discontinue was not due to any safety concerns in the study.
No further clinical development in CF is planned at this time.
This program was sponsored by Gilead. It was conducted within the Therapeutics Development Network.
Recent GS-5745 Studies
Closed to Enrollment
Sign up for clinical trial alerts
Get email updates about clinical trials that matter to you.
Explore clinical trials
Be a part of the movement transforming the future of cystic fibrosis treatment.Learn More